Triptolide prevents bone destruction in the collagen-induced arthritis model of rheumatoid arthritis by targeting RANKL/RANK/OPG signal pathway

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Liu, Chunfang ^a   Zhang, Yanqiong ^a   Kong, Xiangying ^a   Zhu, Liuluan ^b   Pang, Jian ^c   Xu, Ying ^a   Chen, Weiheng ^d   Zhan, Hongsheng ^c   Lu, Aiping ^a   Lin, Na ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SHUGUANG HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d WANGJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; MESSENGER RNA; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRIPTOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DESTRUCTION; BONE MASS; CELL COUNT; COCULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; FIBROBLAST; HUMAN; HUMAN CELL; LD 50; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM; THICKNESS; TRABECULAR BONE;

EID: 84876547494     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/626038     Document Type: Article

References (33)

1. Böhler C., Radner H., Ernst M., Binder A., Stamm T., Aletaha D., Smolen J. S., Köller M., Rheumatoid arthritis and falls: the influence of disease activity. Rheumatology 2012 51 2051 2057
2. Gravallese E. M., Bone destruction in arthritis. Annals of the Rheumatic Diseases 2002 61 2 ii84 ii86 2-s2.0-0036839553 (Pubitemid 35221724)
3. Nanke Y., Yago T., Kotake S., The effects of disease modifying anti-rheumatic drugs on osteoclastogenesis and bone destruction in rheumatoid arthritis. Nihon Rinsho Meneki Gakkai Kaishi 2011 34 493 500
4. Stolina M., Schett G., Dwyer D., Vonderfecht S., Middleton S., Duryea D., Pacheco E., Van G., Bolon B., Feige U., Zack D., Kostenuik P., RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Research & Therapy 2009 11, article R187
5. Bai Y. D., Yang F. S., Xuan K., Bai Y. X., Wu B. L., Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment. Medical Hypotheses 2008 71 2 256 258 2-s2.0-45649084334 10.1016/j.mehy.2008.03.021
6. Bezerra M. C., Carvalho J. F., Prokopowitsch A. S., Pereira R. M. R., RANK, RANKL and osteoprotegerin in arthritic bone loss. Brazilian Journal of Medical and Biological Research 2005 38 2 161 170 2-s2.0-15044344799 (Pubitemid 40378401)
7. Geusens P., The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 2012 4 225 233
8. Ho T. Y., Santora K., Chen J. C., Frankshun A. L., Bagnell C. A., Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. Bone 2011 48 6 1346 1353 2-s2.0-79955918439 10.1016/j.bone.2011.03. 684
9. Saeki Y., Matsui T., Saisho K., Tohma S., Current treatments of rheumatoid arthritis: from the "NinJa" registry. Expert Review of Clinical Immunology 2012 8 455 465
10. Xiao C., Zhou J., He Y., Jia H., Zhao L., Zhao N., Lu A., Effects of triptolide from Radix Tripterygium wilfordii (Leigongteng) on cartilage cytokines and transcription factor NF- B: a study on induced arthritis in rats. Chinese Medicine 2009 4, article 13 2-s2.0-67651062342 10.1186/1749-8546-4-13
11. Wang J., Wang A., Zeng H., Liu L., Jiang W., Zhu Y., Xu Y., Effect of triptolide on T-cell receptor beta variable gene mRNA expression in rats with collagen-induced arthritis. The Anatomical Record 2012 295 922 927
12. Xue M., Jiang Z. Z., Liu J. P., Zhang L. Y., Wang T., Wang H., Liu L., Zhou Z. X., Comparative study on the anti-inflammatory and immune suppressive effect of Wilforlide A. Fitoterapia 2010 81 8 1109 1112 2-s2.0-78549296681 10.1016/j.fitote.2010.07.007
13. Goldbach-Mansky R., Wilson M., Fleischmann R., Olsen N., Silverfield J., Kempf P., Kivitz A., Sherrer Y., Pucino F., Csako G., Costello R., Pham T. H., Snyder C., Van Der Heijde D., Tao X., Wesley R., Lipsky P. E., Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2009 151 4 229 240, W49-W51 2-s2.0-69149101082
14. Matta R., Wang X., Ge H., Ray W., Nelin L. D., Liu Y., Triptolide induces anti-inflammatory cellular responses. American Journal of Translational Research 2009 1 3 267 282 2-s2.0-77951732252
15. Pan X. D., Chen X. C., Advances in the study of immunopharmacological effects and mechanisms of extracts of Tripterygium wilfordii Hook. f. in neuroimmunologic disorders. Yaoxue Xuebao 2008 43 12 1179 1185 2-s2.0-57749189607
16. Chen Z. K., Wang N., Lu H. S., Overexpression of programmed cell death 5 factor enhances triptolides-induced fibroblast-like synoviocytes apoptosis in rheumatoid arthritis. Beijing Da Xue Xue Bao 2008 40 6 567 571 2-s2.0-77953013585
17. Wang Y., Jia L., Wu C. Y., Triptolide inhibits the differentiation of Th17 cells and suppresses collagen-induced arthritis. Scandinavian Journal of Immunology 2008 68 4 383 390 2-s2.0-51349088720 10.1111/j.1365-3083.2008.02147.x
18. Lu Y., Wang W. J., Leng J. H., Cheng L. F., Feng L., Yao H. P., Inhibitory effect of triptolide on interleukin-18 and its receptor in rheumatoid arthritis synovial fibroblasts. Inflammation Research 2008 57 6 260 265 2-s2.0-46449120567 10.1007/s00011-007-7128-9
19. Yifan W., Dengming W., Zheng L., Yanping L., Junkan S., Triptolide inhibits CCR5 expressed in synovial tissue of rat adjuvant-induced arthritis. Pharmacological Reports 2007 59 6 795 799 2-s2.0-42549170631 (Pubitemid 351586575)
20. Hu Y., Cheng W., Cai W., Yue Y., Li J., Zhang P., Advances in research on animal models of rheumatoid arthritis. Clinical Rheumatology 2012 32 2 161 165 10.1007/s10067-012-2041-1
21. Myers L. K., Rosloniec E. F., Cremer M. A., Kang A. H., Collageninduced arthritis, an animal model of autoimmunity. Life sciences 1878 61 1861 1872
22. Lin N., Liu C., Xiao C., Jia H., Imada K., Wu H., Ito A., Triptolide, a diterpenoid triepoxide, suppresses inflammation and cartilage destruction in collagen-induced arthritis mice. Biochemical Pharmacology 2007 73 1 136 146 2-s2.0-33845336176 10.1016/j.bcp.2006.08.027 (Pubitemid 44872877)
23. Lin N., Sato T., Ito A., Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts. Arthritis & Rheumatism 2001 44 2193 2200 (Pubitemid 33644065)
24. Rall L. C., Roubenoff R., Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology 2004 43 10 1219 1223 2-s2.0-5444268665 10.1093/rheumatology/keh321 (Pubitemid 39359292)
25. Jou I. M., Shiau A. L., Chen S. Y., Wang C. R., Shieh D. B., Tsai C. S., Wu C. L., Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis. Arthritis & Rheumatism 2005 52 1 339 344 2-s2.0-12344331258 10.1002/art.20746 (Pubitemid 40129267)
26. Nakano K., Okada Y., Saito K., Tanaka Y., Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis & Rheumatism 2004 50 8 2450 2458 2-s2.0-4043110719 10.1002/art.20367 (Pubitemid 39062704)
27. van Holten J., Reedquist K., Sattonet-Roche P., Smeets T. J., Plater-Zyberk C., Vervoordeldonk M. J., Tak P. P., Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Research & Therapy 2004 6 3 R239 R249 2-s2.0-17644372231
28. Anderson J., Caplan L., Yazdany J., Robbins M. L., Neogi T., Michaud K., Saag K. G., 'Dell JR O., Kazi S., Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care & Research 2012 64 640 647
29. Strand V., Cohen S., Schiff M., Weaver A., Fleischmann R., Cannon G., Fox R., Moreland L., Olsen N., Furst D., Caldwell J., Kaine J., Sharp J., Hurley F., Loew-Friedrich I., Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Archives of Internal Medicine 1999 159 21 2542 2550 2-s2.0-0033596065 10.1001/archinte.159.21.2542
30. Le Goff B., Soltner E., Charrier C., Maugars Y., Rédini F., Heymann D., Berthelot J. M., A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Research & Therapy 2009 11 6, article R185 2-s2.0-77952538875 10.1186/ar2877
31. Braun T., Zwerina J., Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Research & Therapy 2011 13, article 235
32. Sato K., Takayanagi H., Osteoclasts, rheumatoid arthritis, and osteoimmunology. Current Opinion in Rheumatology 2006 18 4 419 426 2-s2.0-33748032383 10.1097/01.bor.0000231912.24740.a5 (Pubitemid 44297289)
33. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., Koshihara Y., Oda H., Nakamura K., Tanaka S., Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis & Rheumatism 2000 43 259 269 (Pubitemid 30395733)